The African continent is considered the largest high endemic area for the oncogenic
retrovirus HTLV-1 with an estimated two to five million infected individuals. However, data on …

Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human
retrovirus discovered in 1980. It is estimated that around 10–20 million people are infected …

The prevalence of antibodies detected by ELISA against human T-lymphotropic viruses, type
I (HTLV-I) and type III (HTLV-III-LAV), is described in a comparative serosurvey in the French …

Human T cell leukemia/lymphoma virus Type 1 and 2 (HTLV-1 and HTLV-2), together with
their simian counterparts (STLV-1, STLV-2), belong to the Primate T lymphotropic viruses …

The human T-cell leukemia virus type 1 (HTLV-1), identified as the first human oncogenic
retrovirus 30 years ago, is not an ubiquitous virus. HTLV-1 is present throughout the world …

Human T cell leukemia virus type 1 (HTLV-1) was the first discovered human retrovirus and
the etiologic agent of adult T-cell leukemia and HTLV-1-associated myelopathy/tropical …

HTLV-1 was the first described human retrovirus and was soon found to be associated with
severe clinical diseases, including a devastating lymphoma/leukemia and other …

Human T-cell leukaemia virus 1 (HTLV-1) is the most potent carcinogenic oncovirus and
potentially the most oncogenic risk factor including chem ical carcinogens. 1 A unique and …

Human T Cell leukemia/lymphoma virus type I, the first human oncogenic retrovirus, is the
aetiological factor of Adult T cell leukemia (ATL), a CD4+ malignant lymphoproliferative …

Human T cell leukemia virus (HTLV-1) is an oncoretrovirus that infects at least 10 million
people worldwide. HTLV-1 exhibits a remarkable genetic stability, however, viral strains …